Dermatology

Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution

This Phase 2b randomized clinical trial demonstrates that vixarelimab, a monoclonal antibody targeting OSMRβ, significantly reduces pruritus and promotes skin lesion clearance in patients with moderate-to-severe prurigo nodularis, offering